跳到正文
原文
MedPage Today·· 10 天前精选AI 评分70

RFK Jr. 关于肽类药物的担忧:监管政策引发争议

RFK Jr. Is Ushering in Peptides. As an Oncologist, Here Are My Concerns.

AI 导读

作者指出,HHS宣布了一项关于六种未获批准肽类药物的临时执法豁免政策,但缺乏临床证据支持。作者担心这些药物在未充分研究前的广泛使用可能带来风险。

推荐理由

作者对未获批准的肽类药物的监管政策提出担忧,强调需要更多临床证据。

正文 · AI 翻译

译文尚不完整,完整内容请切换到原文。

— 临床证据尚未跟上商业热情

by Gilberto de Lima Lopes Junior, MD, MBA

2026年11月10日 • 5 min read

On July 13, 2025, at a Las Vegas hotel hosting the Revolution Against Aging and Death Festival, two women were taken away in ambulances. Both had received injections containing experimental peptides at a conference booth. Both became seriously ill and required ventilators. One mixture was believed to contain MOTS-c, P21, BPC-157, and TB4, substances promoted for tissue repair, metabolic health, and longevity.

Both women recovered. Nevada regulators subsequently imposed $35,000 in fines on four parties involved. But investigators could not establish what caused the reactions. They were unable to obtain the injected products for laboratory testing, and their exact contents remain unverified.

这正是我最担心的:两名女性经历了危及生命的反应,但调查人员无法确定她们确切收到了什么。

Now, Washington is opening a regulatory path for some of these unproven peptides. On October 28, HHS announced an interim enforcement-discretion policy covering six peptides: BPC-157, MOTS-c, TB-500, KPV, Semax, and Epitalon. Under specified conditions, the government does not intend to take enforcement action against licensed pharmacies and physicians compounding these substances while the FDA considers formal rulemaking.

这不是FDA的批准,也不确立安全性和有效性。尽管HHS政策包括了进步的保障措施,但在临床证据尚未跟上商业热情的情况下,该政策也允许更广泛的使用。

The question is not whether peptides have therapeutic potential. Many of them do. The question is whether that potential justifies their use before we know whether they work and are safe. The policy followed a July meeting of the FDA's Pharmacy Compounding Advisory Committee, which voted eight to six with one abstention, to recommend BPC-157 for the compounding list. It also endorsed five of the other six substances considered.

FDA reviewers had reached a different conclusion. Their briefing documents found insufficient evidence to support adding any of the seven substances. For BPC-157, evaluated for ulcerative colitis, they could not establish effectiveness. For several others, including TB-500, KPV, MOTS-c, and Epitalon, human safety studies were absent or extremely limited. Reviewers also identified problems with product characterization.

我职业生涯的大部分时间都在进行肿瘤学临床试验,包括对现在全球使用的免疫疗法和靶向药物的研究。我见过有前景的机制未能转化为患者获益,并在治疗常规使用后出现了意想不到的毒性。临床开发过程缓慢、昂贵且经常令人失望。但这是区分有前景的假设和有用药物的方式。我们应该使审查过程更高效,而不是绕过它。

I see a particular oncologic concern with the premature movement on peptides. Experimental studies suggest BPC-157 may stimulate angiogenesis, the formation of new blood vessels, through pathways involving VEGFR2 and endothelial nitric oxide synthase. Angiogenesis supports normal tissue repair. It is also a process many tumors exploit to sustain growth. This does not mean BPC-157 causes cancer or promotes tumor progression -- we lack human evidence to make that claim. But neither can we definitively exclude such effects, particularly with prolonged exposure or in patients with existing or previously treated malignancies.

在肿瘤学中,我们经常遇到作用于正常组织和恶性组织共享途径的治疗方法。在一种情况下有益的生物活性可能在另一种情况下产生意想不到的后果。不应假设有害,而应进行调查。

还存在适应症不符的问题。FDA 评估 BPC-157 用于溃疡性结肠炎,而商业兴趣则集中在肌腱损伤、运动恢复和抗衰老。一种适应症的证据不能证明另一种适应症的安全性和有效性,尤其是在剂量、给药途径和持续时间方面存在差异的情况下。

The HHS policy includes safeguards worth acknowledging: appropriately sourced ingredients, documentation of identity and purity, single-ingredient preparations, labeling, serious adverse-event reporting, and patient-specific prescriptions. These address genuine problems in the existing peptide market. Patients already obtain experimental substances through poorly regulated online suppliers. Licensed compounding under defined conditions could reduce some risks.

但我们必须区分三个问题:

  • 产品是否如其所声称的那样?
  • 它是否安全?
  • 它是否对患者有益?

制造控制有助于回答第一个问题。毒理学和临床研究解决第二个问题。精心设计的试验建立第三个问题。分析证书不能证明有效性。处方不能证明有利的风险比。不良事件报告不能替代前瞻性安全性研究。

配制在临床中具有重要意义,当商业制剂不适合时,满足个体需求。但它不应取代药物开发。当实验性肽通过健康诊所、远程医疗和社会媒体向数千名患者推销以类似目的时,它们开始类似于商业药物,即使处方是个性化的。

同样的原则也适用于延寿医学。对细胞衰老、mTOR 信号传导、代谢调节和细胞重编程的研究提供了真正的机会。我欢迎这些研究。但在小鼠中的结果并不能证明人类受益,而广泛的使用缺乏系统研究不一定能产生可靠的知识。我们应该加速研究,而不是用不受控制的实验取代它。

The HHS policy remains interim, with public comments invited through November 13. That process should address dosing, clinical benefit, long-term safety, adverse-event surveillance, and opportunities to link expanded access to systematic evidence generation.

创新与监管并非二选一。良好的监管能够促进创新,同时保护患者免受不确定的益处和风险。在癌症药物开发中,我们一再学到这一点:一个令人信服的作用机制启动了一个研究项目。它并不能证明药物是有效的。

创新值得鼓励。而患者则需要证据。

来源:MedPage Today · medpagetoday.com